Literature DB >> 20331462

Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children.

T O B Eden, R Pieters, S Richards.   

Abstract

Vincristine plus steroid pulses have long been a part of maintenance treatment in many protocols for childhood acute lymphoblastic leukaemia (ALL). A collaborative individual patient data meta-analysis of all randomised trials of the addition of vincristine plus prednisone/prednisolone (VP) pulses in childhood ALL was updated and extended to include trials comparing vincristine plus dexamethasone (VD) pulses to maintenance without pulses. VP pulses improved event-free survival (EFS) (70.1% vs. 62.0% at 5 years; odds ratio (OR) = 0.71; 95% confidence interval (CI) = 0.61-0.84; P = 0.00004); VD pulses did not have a significant effect (80.9% vs. 79.9% 5 year EFS; OR = 0.94; 95% CI = 0.80-1.11; P = 0.5). Heterogeneity between groups (VP or VD) was significant (P = 0.02). Neither treatment clearly affected overall survival. The difference between the VP and VD results is probably due to the greater early intensity of the backbone of the VD trial protocols and improved outcome seen in the VD trials, which were more recent. Pulses may still be useful in cases where less intensive early therapy is used and the balance between these treatments in terms of both effectiveness and toxicity needs to be considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331462     DOI: 10.1111/j.1365-2141.2010.08148.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  IKZF1 gene polymorphisms increased the risk of childhood acute lymphoblastic leukemia in an Iranian population.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Mohsen Taheri
Journal:  Tumour Biol       Date:  2016-01-21

2.  Apoptotic role of IKK in T-ALL therapeutic response.

Authors:  Irene Riz; Lynnsey A Zweier-Renn; Ian Toma; Teresa S Hawley; Robert G Hawley
Journal:  Mol Cancer Res       Date:  2011-07-05       Impact factor: 5.852

Review 3.  Treatment of pediatric acute lymphoblastic leukemia.

Authors:  Stacy L Cooper; Patrick A Brown
Journal:  Pediatr Clin North Am       Date:  2014-10-18       Impact factor: 3.278

4.  Inhibition of S100A6 induces GVL effects in MLL/AF4-positive ALL in human PBMC-SCID mice.

Authors:  H Tamai; K Miyake; H Yamaguchi; T Shimada; K Dan; K Inokuchi
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

Review 5.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

Authors:  Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

6.  Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.

Authors:  Anne L Angiolillo; Reuven J Schore; John A Kairalla; Meenakshi Devidas; Karen R Rabin; Patrick Zweidler-McKay; Michael J Borowitz; Brent Wood; Andrew J Carroll; Nyla A Heerema; Mary V Relling; Johann Hitzler; Ashley R Lane; Kelly W Maloney; Cindy Wang; Mylène Bassal; William L Carroll; Naomi J Winick; Elizabeth A Raetz; Mignon L Loh; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2021-01-07       Impact factor: 44.544

7.  Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation.

Authors:  H Tamai; K Miyake; H Yamaguchi; M Takatori; K Dan; K Inokuchi; T Shimada
Journal:  Blood Cancer J       Date:  2011-11-04       Impact factor: 11.037

8.  Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study.

Authors:  Claire L Vale; Larysa H M Rydzewska; Maroeska M Rovers; Jonathan R Emberson; François Gueyffier; Lesley A Stewart
Journal:  BMJ       Date:  2015-03-06

9.  Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.

Authors:  Wenyu Yang; Jiaoyang Cai; Shuhong Shen; Ju Gao; Jie Yu; Shaoyan Hu; Hua Jiang; Yongjun Fang; Changda Liang; Xiuli Ju; Xuedong Wu; Xiaowen Zhai; Xin Tian; Ningling Wang; Aiguo Liu; Hui Jiang; Runming Jin; Lirong Sun; Minghua Yang; Alex W K Leung; Kaili Pan; Yingchi Zhang; Jing Chen; Yiping Zhu; Hui Zhang; Chunfu Li; Jun J Yang; Cheng Cheng; Chi-Kong Li; Jingyan Tang; Xiaofan Zhu; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2021-07-27       Impact factor: 54.433

Review 10.  Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.

Authors:  Kjeld Schmiegelow; Stine N Nielsen; Thomas L Frandsen; Jacob Nersting
Journal:  J Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.